In this issue:
Adverse events with IL-17 and IL-23 inhibitors
Risankizumab for moderate-to-severe plaque psoriasis
Tildrakizumab dose adjustments for plaque psoriasis
Histologic characteristics of TNF-α inhibitor-induced psoriasis
Apremilast for psoriasis and psoriatic arthritis
Long-term efficacy and safety of apremilast in psoriatic arthritis
Treatment of erythrodermic psoriasis with biologics
Long-term safety of brodalumab for plaque psoriasis
Treating psoriasis and atopic dermatitis during the COVID-19 pandemic
COVID-19 and biologic therapy for psoriasis
Please login below to download this issue (PDF)